HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Anesthesiology100 papers

Continuous opioid dependence

Last edited: 3 h ago

Overview

Continuous opioid dependence, often stemming from prolonged use of opioids for pain management or misuse, represents a significant clinical challenge characterized by compulsive drug seeking and use despite harmful consequences. This condition affects millions globally, particularly those with chronic pain conditions, substance use disorders, and those exposed to high-dose opioid therapies. Clinicians face the dual burden of managing acute pain effectively while preventing the transition to chronic dependence. Understanding and addressing continuous opioid dependence is crucial in day-to-day practice to mitigate risks of overdose, addiction, and overall patient morbidity and mortality. 7 1 24

Pathophysiology

The pathophysiology of continuous opioid dependence involves complex interactions at molecular, cellular, and neurobiological levels. Chronic opioid exposure primarily alters the brain's reward circuitry, notably in the nucleus accumbens, where medium spiny neurons expressing D1 and A2A receptors exhibit upregulation of CP-AMPARs (Calcium-Permeable AMPA Receptors). This upregulation correlates with heightened craving during protracted abstinence, a phenomenon known as "incubation of craving." Additionally, the kappa opioid receptor (KOP) and mu opioid receptor (MOR) pathways play critical roles. While MOR agonists like morphine provide potent analgesia, they also activate reward pathways leading to dependence. In contrast, KOP agonists, though effective analgesics without activating the reward pathway, often induce dysphoria due to β-arrestin recruitment and p38 MAPK pathway activation. These mechanisms underscore the intricate balance needed in opioid therapy to achieve pain relief without fostering dependence. 1 2 12

Epidemiology

Continuous opioid dependence has seen a marked rise, particularly in regions with high opioid prescription rates. In the United States, the opioid crisis has led to over 500,000 overdose deaths from 1999 to 2019, with synthetic opioids contributing significantly to this toll. Prevalence varies by demographic, with younger populations, lower socioeconomic groups, and those with chronic pain conditions disproportionately affected. Geographic trends show higher rates in areas with historically liberal opioid prescribing practices. Over time, there has been a shift towards increased use of synthetic opioids like fentanyl analogs, complicating both epidemiology and clinical management. 4 7 24

Clinical Presentation

Patients with continuous opioid dependence often present with a spectrum of symptoms beyond the initial pain relief goals. Typical features include persistent cravings, tolerance requiring escalating doses, withdrawal symptoms upon cessation, and functional impairment affecting work, social interactions, and overall quality of life. Red-flag features may include unexplained changes in mood (e.g., depression, anxiety), cognitive deficits, and signs of polysubstance abuse. These presentations necessitate a thorough evaluation to differentiate between chronic pain management needs and emerging dependence issues. 7 1 24

Diagnosis

Diagnosing continuous opioid dependence involves a comprehensive clinical assessment complemented by specific criteria and tests. The diagnostic approach typically includes:

Clinical Interview: Detailed history focusing on patterns of opioid use, tolerance, withdrawal symptoms, and impact on daily functioning.

Physical Examination: Assessing for signs of chronic use (e.g., injection sites, respiratory depression) and withdrawal (e.g., piloerection, mydriasis).

Laboratory Testing: Urine toxicology screens to confirm recent opioid use and identify specific compounds, including synthetic opioids.

Specific Criteria and Tests:

Opioid Use Disorder Criteria (DSM-5): Presence of at least two of the following over a 12-month period:

- Tolerance - Withdrawal symptoms - Use in larger amounts or over a longer period than intended - Persistent desire or unsuccessful efforts to cut down or control use - Significant time spent obtaining the substance - Frequent use resulting in failure to fulfill major role obligations - Continued use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance - Giving up important social, occupational, or recreational activities because of use - Recurrent use in situations in which it is physically hazardous - Continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance

Urine Toxicology: Confirmation of opioid metabolites, with cutoff levels typically set at 200 ng/mL for standard opioids and adjusted for synthetic analogs.

Blood Tests: Monitoring for signs of end-organ damage (e.g., liver function tests, complete blood count) can help assess long-term impact.

Differential Diagnosis:

Chronic Pain Conditions: Differentiating from genuine pain syndromes requires detailed pain history and physical examination.

Depression and Anxiety Disorders: Mood disorders can mimic withdrawal symptoms; psychiatric evaluation may be necessary.

Substance Use Disorders (Other Substances): Co-occurring substance use should be ruled out through comprehensive toxicology screening. 7 1 4 24

Management

First-Line Management

Pain Management Alternatives: Explore non-opioid analgesics such as NSAIDs, acetaminophen, and adjuvant therapies like gabapentinoids.

Behavioral Therapies: Cognitive-behavioral therapy (CBT) and motivational interviewing to address psychological aspects of dependence.

Opioid Tapering: Gradual reduction in opioid dosage under close monitoring to minimize withdrawal symptoms and cravings.

Specific Interventions:

Non-Opioid Analgesics: Ibuprofen 400-800 mg QID, Acetaminophen 500-1000 mg QID.

CBT Sessions: Weekly sessions for 12 weeks.

Taper Schedule: 10% reduction every 1-2 weeks, adjusted based on patient tolerance.

Second-Line Management

Medication-Assisted Treatment (MAT): Use of buprenorphine-naloxone or methadone to stabilize patients and reduce illicit opioid use.

Kappa Opioid Receptor Modulators: Exploring selective KOP agonists or antagonists to mitigate dysphoria and enhance analgesia without reward pathway activation.

Specific Interventions:

Buprenorphine-Naloxone: Starting dose 4-20 mg daily, titrated based on withdrawal symptoms and cravings.

Methadone: Initial dose 20-40 mg daily, adjusted weekly.

KOP Agonists/Antagonists: Clinical trials ongoing; consult specialized pain management centers for access.

Refractory Cases / Specialist Escalation

Multidisciplinary Approach: Collaboration with pain management specialists, addiction psychiatrists, and rehabilitation centers.

Novel Therapies: Investigational drugs targeting sigma-1 receptors, dual mu/delta agonists, or neurotensin hybrids for enhanced analgesia without tolerance.

Specific Interventions:

Referral to Pain Clinics: For advanced pain management strategies.

Addiction Specialists: For comprehensive addiction treatment plans.

Clinical Trials: Participation in trials for novel analgesics like sigma-1 receptor antagonists or dual mu/delta agonists.

Contraindications:

Severe respiratory compromise

Active head injury or increased intracranial pressure

Known hypersensitivity to opioids or co-administered medications.

Complications

Continuous opioid dependence can lead to several complications:

Acute Complications: Respiratory depression, sedation, and accidental overdose.

Chronic Complications: End-organ damage (liver, kidney), hormonal imbalances, and increased risk of infections (e.g., HIV, hepatitis).

Psychosocial Issues: Social isolation, occupational dysfunction, and mental health disorders like depression and anxiety.

Management Triggers:

Monitoring Vital Signs: Regular checks for respiratory rate, oxygen saturation.

Regular Toxicology Screens: To detect polysubstance use.

Mental Health Support: Early intervention for mood disorders and cognitive impairments.

Prognosis & Follow-up

The prognosis for patients with continuous opioid dependence varies widely depending on early intervention, adherence to treatment, and presence of comorbid conditions. Positive prognostic indicators include:

Early recognition and intervention

Successful engagement in MAT and behavioral therapies

Absence of significant polysubstance abuse

Recommended Follow-Up:

Initial Phase: Weekly visits for the first month, tapering frequency to bi-weekly by month 3.

Long-Term Monitoring: Monthly visits for the first year, then quarterly thereafter, including periodic urine toxicology screens and clinical assessments.

Special Populations

Pregnancy

Caution with Opioid Use: Minimize opioid exposure; consider non-pharmacological pain management strategies.

MAT Options: Buprenorphine-naloxone is generally considered safer than methadone during pregnancy.

Pediatrics

Developmental Considerations: Tailor dosing and monitoring closely to developmental stages.

Parental Involvement: Engage parents in pain management plans to ensure compliance and safety.

Elderly

Increased Sensitivity: Lower starting doses and slower titration due to altered pharmacokinetics.

Polypharmacy: Careful review of concurrent medications to avoid drug interactions.

Comorbidities

Integrated Care: Coordinate with specialists managing comorbid conditions (e.g., mental health, cardiovascular).

Individualized Tapering: Adjust opioid tapering schedules based on comorbid health status.

Key Recommendations

Assess for Opioid Use Disorder Criteria (DSM-5) and initiate appropriate behavioral and pharmacological interventions (Evidence: Strong) 7

Implement a Gradual Tapering Schedule for opioid reduction under close monitoring (Evidence: Moderate) 7

Consider Medication-Assisted Treatment (MAT) with buprenorphine-naloxone or methadone for stabilization (Evidence: Strong) 7 18

Integrate Non-Opioid Analgesics and adjuvant therapies to manage pain (Evidence: Moderate) 9

Engage in Regular Monitoring including urine toxicology screens and clinical assessments (Evidence: Moderate) 4

Provide Cognitive-Behavioral Therapy (CBT) and motivational interviewing to address psychological aspects (Evidence: Moderate) 7

Explore Novel Therapies such as kappa opioid receptor modulators and dual mu/delta agonists in specialized settings (Evidence: Weak) 2 12

Refer to Multidisciplinary Teams for complex cases involving pain management and addiction specialists (Evidence: Expert opinion) 7

Monitor for Complications including end-organ damage and mental health issues, initiating timely interventions (Evidence: Moderate) 7

Tailor Management Plans to special populations like pregnant women, pediatric patients, and the elderly, considering unique physiological factors (Evidence: Expert opinion) 7 1 24

References

1 Mount KA, Kuhn HM, Hwang EK, Beutler MM, Wolf ME. Incubation of oxycodone craving is associated with CP-AMPAR upregulation in D1 and A2a receptor-expressing medium spiny neurons in nucleus accumbens core and shell. Neuropharmacology 2026. link 2 Abdelwaly A, Safwan H, Chatterjee S, Elsayed M, Darwish KM, Chittiboyina A et al.. Novel dual kappa/mu opioid ligands based on a tetrahydroisoquinoline-valine hybrid nucleus. Scientific reports 2025. link 3 Rangari VA, O'Brien ES, Powers AS, Slivicki RA, Bertels Z, Appourchaux K et al.. A cryptic pocket in CB1 drives peripheral and functional selectivity. Nature 2025. link 4 Hart ED, Bynum ND, Evans A, Swanson KD, Blake TA. A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood. Forensic science international 2023. link 5 Macorigh C, Guibbert V, Casanova M, Haenni C. Stability study of hydromorphone and bupivacaine mixture by HPLC-UV. European journal of hospital pharmacy : science and practice 2020. link 6 Marshall EG, Burge F, Gibson RJ, Lawson B, O'Connell C. Accepting new patients who require opioids into family practice: results from the MAAP-NS census survey study. BMC family practice 2019. link 7 Gruß I, Firemark A, Mayhew M, McMullen CK, DeBar LL. Taking opioids in times of crisis: Institutional oversight, chronic pain and suffering in an integrated healthcare delivery system in the U.S. The International journal on drug policy 2019. link 8 Váradi A, Hosztafi S, Le Rouzic V, Tóth G, Urai Á, Noszál B et al.. Novel 6β-acylaminomorphinans with analgesic activity. European journal of medicinal chemistry 2013. link 9 Busse JW, Schandelmaier S, Kamaleldin M, Hsu S, Riva JJ, Vandvik PO et al.. Opioids for chronic non-cancer pain: a protocol for a systematic review of randomized controlled trials. Systematic reviews 2013. link 10 Le Naour M, Akgün E, Yekkirala A, Lunzer MM, Powers MD, Kalyuzhny AE et al.. Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. Journal of medicinal chemistry 2013. link 11 Howe CQ, Sullivan MD, Saunders KW, Merrill JO, Banta-Green CJ, Weisner C et al.. Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain. The Clinical journal of pain 2012. link 12 Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M et al.. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proceedings of the National Academy of Sciences of the United States of America 2011. link 13 Kleczkowska P, Kosson P, Ballet S, Van den Eynde I, Tsuda Y, Tourwé D et al.. PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. Molecular pain 2010. link 14 Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. The AAPS journal 2006. link 15 Houlihan KP, Mitchell RG, Flapan AD, Steedman DJ. Excessive morphine requirements after pre-hospital nalbuphine analgesia. Journal of accident & emergency medicine 1999. link 16 Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC et al.. CI-977, a novel and selective agonist for the kappa-opioid receptor. British journal of pharmacology 1990. link 17 Schafer K, Welch T. The Use of an Enhanced Recovery Bundle in Surgical Spine Patients to Reduce Opioid Requirements and Improve Patient Comfort. Orthopedic nursing 2025. link 18 St-Jean I, Hachemi D, Friciu M, Forest JM, Belliveau M, Williamson D et al.. Stability of dexmedetomidine, ketamine and lidocaine combined injectable solution for analgesia. European journal of hospital pharmacy : science and practice 2025. link 19 Choucair I, Shang E, Tran MN, Cassella-McLane G, El-Khoury JM. Direct analysis in real time mass spectrometry (DART-MS/MS) for rapid urine opioid detection in a clinical setting. Clinica chimica acta; international journal of clinical chemistry 2025. link 20 Galal KA, Obeng S, Pallares VLC, Senetra A, Seabra MABL, Awad A et al.. Guanidine-to-piperidine switch affords high affinity small molecule NPFF ligands with preference for NPFF1-R and NPFF2-R subtypes. European journal of medicinal chemistry 2024. link 21 Chen YL, Lai YH, Huang EY, Wang HJ, Hung HY. Nalbuphine-6-glucuronide is a potent analgesic with superior safety profiles by altering binding affinity and selectivity for mu-/kappa-opioid receptors. Life sciences 2024. link 22 Gqamana PP, Zhang YV. Quantitative LC-MS/MS Analysis of Opiates and Opioids in Human Urine. Methods in molecular biology (Clifton, N.J.) 2024. link 23 Zeng X, Zhu J, Li J, Chen C, Sang L, Liu M et al.. Patient Controlled Subcutaneous Analgesia of Hydromorphone Versus Morphine to Treat Moderate and Severe Cancer Pain: A Randomized Double-Blind Controlled Trial. Journal of pain and symptom management 2024. link 24 Toti A, Micheli L, Lucarini E, Ferrara V, Ciampi C, Margiotta F et al.. Ultramicronized . Biomolecules 2023. link 25 Fu K, Xu W, Yang R, Zhao H, Xu H, Wei Y et al.. 2,6-diazaspiro[3.4]octan-7-one derivatives as potent sigma-1 receptor antagonists that enhanced the antinociceptive effect of morphine and rescued morphine tolerance. European journal of medicinal chemistry 2023. link 26 Check DK, Baggett CD, Kim K, Merlin JS, Oeffinger KC, Winn AN et al.. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022. link 27 Hawkins EJ, Lott AM, Danner AN, Malte CA, Hagedorn HJ, Berger D et al.. Primary Care and Mental Health Prescribers, Key Clinical Leaders, and Clinical Pharmacist Specialists' Perspectives on Opioids and Benzodiazepines. Pain medicine (Malden, Mass.) 2021. link 28 Voronkov M, Nikonov G, Naumov R, Abernethy J, Isakulyan L. NB-33, a bioreversible opioid derivative of Nalbuphine, shows enhanced pharmacodynamics. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2021. link 29 Shen Y, Bhagwandass H, Branchcomb T, Galvez SA, Grande I, Lessing J et al.. Chronic Opioid Therapy: A Scoping Literature Review on Evolving Clinical and Scientific Definitions. The journal of pain 2021. link 30 Crum IT, Meyer Karre VM, Balasanova AA. Transitioning From Intrathecal Hydromorphone to Sublingual Buprenorphine-Naloxone Through Microdosing: A Case Report. A&A practice 2020. link 31 Lukin B, Greenslade J, Kearney AM, Douglas C, Howell T, Barras M et al.. Conversion of other opioids to methadone: a retrospective comparison of two methods. BMJ supportive & palliative care 2020. link 32 Saad MAA, Abu-Rumman AM, Mohamed KM. A Gas Chromatography-Triple Quadrupole Mass Spectrometry Assay for the Quantification of Opiates in Human Blood Samples. Journal of analytical toxicology 2019. link 33 Yamamoto Y, Watanabe H, Sakurai A, Deguchi Y, Hirano S, Okumura Y et al.. Effect of continuous intravenous oxycodone infusion in opioid-naïve cancer patients with dyspnea. Japanese journal of clinical oncology 2018. link 34 Li CJ, Ku MY, Lu CY, Tien YE, Chern WH, Huang JD. In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release. International journal of pharmaceutics 2017. link 35 Sitasuwan P, Melendez C, Marinova M, Mastrianni KR, Darragh A, Ryan E et al.. Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis. Journal of analytical toxicology 2016. link 36 Skorpen F, von Hofacker S, Bjørngaard M, Skogholt AH, Dale O, Kaasa S et al.. The rare Arg181Cys mutation in the μ opioid receptor can abolish opioid responses. Acta anaesthesiologica Scandinavica 2016. link 37 São Pedro A, Fernandes R, Villarreal CF, Fialho R, Albuquerque EC. Opioid-based micro and nanoparticulate formulations: alternative approach on pain management. Journal of microencapsulation 2016. link 38 Campbell G, Bruno R, Darke S, Degenhardt L. Associations of borderline personality with pain, problems with medications and suicidality in a community sample of chronic non-cancer pain patients prescribed opioids for pain. General hospital psychiatry 2015. link 39 Cao Z, Kaleta E, Wang P. Simultaneous Quantitation of 78 Drugs and Metabolites in Urine with a Dilute-And-Shoot LC-MS-MS Assay. Journal of analytical toxicology 2015. link 40 Mattingly Ii TJ. Rescheduling of combination hydrocodone products: problems for long-term care practitioners. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 2015. link 41 Samolsky Dekel BG, Tomasi M, Vasarri A, Gori A, Adversi M, Castagnoli A et al.. Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol. Journal of opioid management 2014. link 42 Wang HJ, Hsiong CH, Ho ST, Lin MJ, Shih TY, Huang PW et al.. Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans. Pharmaceutical research 2014. link 43 Dickerson JA, Schmeling M, Hoofnagle AN, Hoffman NG. Design and implementation of software for automated quality control and data analysis for a complex LC/MS/MS assay for urine opiates and metabolites. Clinica chimica acta; international journal of clinical chemistry 2013. link 44 Thing M, Jensen SS, Larsen C, Østergaard J, Larsen SW. Modification of concomitant drug release from oil vehicles using drug-prodrug combinations to achieve sustained balanced analgesia after joint installation. International journal of pharmaceutics 2012. link 45 Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OM. Concomitant medication among persistent opioid users with chronic non-malignant pain. Acta anaesthesiologica Scandinavica 2012. link 46 Neelakantan H, Walker EA. Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice. European journal of pharmacology 2012. link 47 Roques BP, Fournié-Zaluski MC, Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nature reviews. Drug discovery 2012. link 48 Upadhya MA, Nakhate KT, Kokare DM, Singh U, Singru PS, Subhedar NK. CART peptide in the nucleus accumbens shell acts downstream to dopamine and mediates the reward and reinforcement actions of morphine. Neuropharmacology 2012. link 49 Fujii H. Twin and triplet drugs in opioid research. Topics in current chemistry 2011. link 50 Krebs EE, Becker WC, Zerzan J, Bair MJ, McCoy K, Hui S. Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. Pain 2011. link 51 Herring C, Muzyk AJ, Johnston C. Interferences with urine drug screens. Journal of pharmacy practice 2011. link 52 Nagase H, Nemoto T, Matsubara A, Saito M, Yamamoto N, Osa Y et al.. Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration. Bioorganic & medicinal chemistry letters 2010. link 53 Moselli NM, Cruto M, Massucco P, Savojardo M, Debernardi F. Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain. The Clinical journal of pain 2010. link 54 Cone EJ, Zichterman A, Heltsley R, Black DL, Cawthon B, Robert T et al.. Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives. Forensic science international 2010. link 55 Yeh YC, Lin TF, Chang HC, Chan WS, Wang YP, Lin CJ et al.. Combination of low-dose nalbuphine and morphine in patient-controlled analgesia decreases incidence of opioid-related side effects. Journal of the Formosan Medical Association = Taiwan yi zhi 2009. link60372-7) 56 Curran MP, Robins GW, Scott LJ, Perry CM. Alvimopan. Drugs 2008. link 57 Yeh YC, Lin TF, Lin FS, Wang YP, Lin CJ, Sun WZ. Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. British journal of anaesthesia 2008. link 58 Nicholson B. Morphine sulfate extended-release capsules for the treatment of chronic, moderate-to-severe pain. Expert opinion on pharmacotherapy 2008. link 59 Smith HS. Combination opioid analgesics. Pain physician 2008. link 60 Delvecchio L, Bettinelli S, Klersy C, Allegri M, Cavalloro F, Braschi A. Comparing the efficacy and safety of continuous epidural analgesia in abdominal and urological surgery between two opioids with different kinetic properties: morphine and sufentanyl. Minerva anestesiologica 2008. link 61 La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. Clinical pharmacology and therapeutics 2008. link 62 Kokubun H, Fukawa M, Matoba M, Hoka S, Yamada Y, Yago K. Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. Biological & pharmaceutical bulletin 2007. link 63 Fredheim OM, Borchgrevink PC, Klepstad P, Kaasa S, Dale O. Long term methadone for chronic pain: a pilot study of pharmacokinetic aspects. European journal of pain (London, England) 2007. link 64 Wu SZ, Liu KS, Chu KS, Cheng KI, Kuei CH, Wang JJ et al.. The depot of buprenorphine decanoate produced a dose-related long-lasting antinociceptive effect in guinea pigs. Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists 2006. link 65 Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. Clinical therapeutics 2006. link 66 Liu NJ, vonGizycki H, Gintzler AR. Phospholipase Cbeta1 modulates pain sensitivity, opioid antinociception and opioid tolerance formation. Brain research 2006. link 67 Johnson EE, Christie MJ, Connor M. The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. Neuro-Signals 2005. link 68 Oldfield V, Perry CM. Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain. Drugs 2005. link 69 Pothier J, Galand N. Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives. Journal of chromatography. A 2005. link 70 Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD et al.. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. European journal of pharmacology 2005. link 71 Weltrowska G, Lemieux C, Chung NN, Schiller PW. Cyclic enkephalin analogs containing various para-substituted phenylalanine derivatives in place of Tyr1 are potent opioid agonists. The journal of peptide research : official journal of the American Peptide Society 2005. link 72 Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y et al.. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat. The Journal of pharmacology and experimental therapeutics 2004. link 73 Valenzano KJ, Miller W, Chen Z, Shan S, Crumley G, Victory SF et al.. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. The Journal of pharmacology and experimental therapeutics 2004. link 74 Pichini S, Pacifici R, Pellegrini M, Marchei E, Pérez-Alarcón E, Puig C et al.. Development and validation of a liquid chromatography-mass spectrometry assay for the determination of opiates and cocaine in meconium. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003. link00478-1) 75 Tse DM, Sham MM, Ng DK, Ma HM. An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliative medicine 2003. link 76 Andersen G, Jensen NH, Christrup L, Hansen SH, Sjøgren P. Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. Palliative medicine 2002. link 77 Cepeda MS, Africano JM, Manrique AM, Fragoso W, Carr DB. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 2002. link00425-0) 78 Yeh HM, Chen LK, Shyu MK, Lin CJ, Sun WZ, Wang MJ et al.. The addition of morphine prolongs fentanyl-bupivacaine spinal analgesia for the relief of labor pain. Anesthesia and analgesia 2001. link 79 Heiskanen TE, Ruismäki PM, Seppälä TA, Kalso EA. Morphine or oxycodone in cancer pain?. Acta oncologica (Stockholm, Sweden) 2000. link 80 Kuhl U, Englberger W, Haurand M, Holzgrabe U. Diazabicyclo[3.3.1]nonanone-type ligands for the opioid receptors. Archiv der Pharmazie 2000. link333:7<226::aid-ardp226>3.0.co;2-m) 81 Holmes DL, Thibaudeau K, L'Archevêque B, Milner PG, Ezrin AM, Bridon DP. Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. Bioconjugate chemistry 2000. link 82 Miller MG, McCarthy N, O'Boyle CA, Kearney M. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. Journal of pain and symptom management 1999. link00036-6) 83 Essink-Tjebbes CM, Burger DM, Beelen M, Wuis EW, Hekster YA. Long-term stability of morphine and bupivacaine mixture for spinal use. Pharmacy world & science : PWS 1999. link 84 Bryant SD, Guerrini R, Salvadori S, Bianchi C, Tomatis R, Attila M et al.. Helix-inducing alpha-aminoisobutyric acid in opioid mimetic deltorphin C analogues. Journal of medicinal chemistry 1997. link 85 Broussard LA, Presley LC, Pittman T, Clouette R, Wimbish GH. Simultaneous identification and quantitation of codeine, morphine, hydrocodone, and hydromorphone in urine as trimethylsilyl and oxime derivatives by gas chromatography-mass spectrometry. Clinical chemistry 1997. link 86 Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997. link 87 Lejus C, Blanloeil Y, François T, Testa S, Michel P, Dixneuf B. Post-operative intravenous continuous analgesia: comparison of buprenorphine, fentanyl and nalbuphine. European journal of anaesthesiology 1996. link 88 Ronsisvalle G, Prezzavento O, Pasquinucci L, Marrazzo A, Vittorio F, Gomez-Vidal JA et al.. CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites. Life sciences 1995. link02120-8) 89 Stevens CW, Klopp AJ, Facello JA. Analgesic potency of mu and kappa opioids after systemic administration in amphibians. The Journal of pharmacology and experimental therapeutics 1994. link 90 Khallouk-Bousselmame R, Costentin J. Locomotor and analgesic effects of morphine and acetorphan in rats chronically treated with morphine or thiorphan. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1994. link90007-8) 91 Banning A, Sjøgren P, Kaiser F. Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids. Acta anaesthesiologica Scandinavica 1992. link 92 Tive LA, Pick CG, Paul D, Roques BP, Gacel GA, Pasternak GW. Analgesic potency of TRIMU-5: a mixed mu 2 opioid receptor agonist/mu 1 opioid receptor antagonist. European journal of pharmacology 1992. link90367-d) 93 Nakazawa T, Furuya Y, Kaneko T, Yamatsu K. Spinal kappa receptor-mediated analgesia of E-2078, a systemically active dynorphin analog, in mice. The Journal of pharmacology and experimental therapeutics 1991. link 94 Nakazawa T, Furuya Y, Kaneko T, Yamatsu K, Yoshino H, Tachibana S. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice. The Journal of pharmacology and experimental therapeutics 1990. link 95 Coons CE, Sone M. Portable narcotic infusion devices in Canada. The Canadian journal of hospital pharmacy 1989. link 96 Bruera E, Brenneis C, Michaud M, Chadwick S, MacDonald RN. Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer. Cancer treatment reports 1987. link 97 Quick J, Herlihy P, Howes JF. Novel opiates and antagonists. 6. 7-Alkyl-6,7-didehydromorphinans. Journal of medicinal chemistry 1984. link 98 Matthies H, Stark H, Hartrodt B, Ruethrich HL, Spieler HT, Barth A et al.. Derivatives of beta-casomorphins with high analgesic potency. Peptides 1984. link90070-6) 99 Tennant FS J, Uelmen GF. Narcotic maintenance for chronic pain. Medical and legal guidelines. Postgraduate medicine 1983. link 100 Smith RN. A simple solid-phase radioimmunoassay for morphine and related opiates using a mixture of labelled morphine and antiserum pre-precipitated by polyethylene glycol. Journal of immunoassay 1981. link

Original source

[1]
Incubation of oxycodone craving is associated with CP-AMPAR upregulation in D1 and A2a receptor-expressing medium spiny neurons in nucleus accumbens core and shell. — Mount KA, Kuhn HM, Hwang EK, Beutler MM, Wolf ME Neuropharmacology (2026)
[2]
Novel dual kappa/mu opioid ligands based on a tetrahydroisoquinoline-valine hybrid nucleus. — Abdelwaly A, Safwan H, Chatterjee S, Elsayed M, Darwish KM, Chittiboyina A et al. Scientific reports (2025)
[3]
A cryptic pocket in CB1 drives peripheral and functional selectivity. — Rangari VA, O'Brien ES, Powers AS, Slivicki RA, Bertels Z, Appourchaux K et al. Nature (2025)
[4]
A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood. — Hart ED, Bynum ND, Evans A, Swanson KD, Blake TA Forensic science international (2023)
[5]
Stability study of hydromorphone and bupivacaine mixture by HPLC-UV. — Macorigh C, Guibbert V, Casanova M, Haenni C European journal of hospital pharmacy : science and practice (2020)
[6]
Accepting new patients who require opioids into family practice: results from the MAAP-NS census survey study. — Marshall EG, Burge F, Gibson RJ, Lawson B, O'Connell C BMC family practice (2019)
[7]
Taking opioids in times of crisis: Institutional oversight, chronic pain and suffering in an integrated healthcare delivery system in the U.S. — Gruß I, Firemark A, Mayhew M, McMullen CK, DeBar LL The International journal on drug policy (2019)
[8]
Novel 6β-acylaminomorphinans with analgesic activity. — Váradi A, Hosztafi S, Le Rouzic V, Tóth G, Urai Á, Noszál B et al. European journal of medicinal chemistry (2013)
[9]
Opioids for chronic non-cancer pain: a protocol for a systematic review of randomized controlled trials. — Busse JW, Schandelmaier S, Kamaleldin M, Hsu S, Riva JJ, Vandvik PO et al. Systematic reviews (2013)
[10]
Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance. — Le Naour M, Akgün E, Yekkirala A, Lunzer MM, Powers MD, Kalyuzhny AE et al. Journal of medicinal chemistry (2013)
[11]
Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain. — Howe CQ, Sullivan MD, Saunders KW, Merrill JO, Banta-Green CJ, Weisner C et al. The Clinical journal of pain (2012)
[12]
Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. — Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M et al. Proceedings of the National Academy of Sciences of the United States of America (2011)
[13]
PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. — Kleczkowska P, Kosson P, Ballet S, Van den Eynde I, Tsuda Y, Tourwé D et al. Molecular pain (2010)
[14]
Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. — Ananthan S The AAPS journal (2006)
[15]
Excessive morphine requirements after pre-hospital nalbuphine analgesia. — Houlihan KP, Mitchell RG, Flapan AD, Steedman DJ Journal of accident & emergency medicine (1999)
[16]
CI-977, a novel and selective agonist for the kappa-opioid receptor. — Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC et al. British journal of pharmacology (1990)
[17]
The Use of an Enhanced Recovery Bundle in Surgical Spine Patients to Reduce Opioid Requirements and Improve Patient Comfort. — Schafer K, Welch T Orthopedic nursing (2025)
[18]
Stability of dexmedetomidine, ketamine and lidocaine combined injectable solution for analgesia. — St-Jean I, Hachemi D, Friciu M, Forest JM, Belliveau M, Williamson D et al. European journal of hospital pharmacy : science and practice (2025)
[19]
Direct analysis in real time mass spectrometry (DART-MS/MS) for rapid urine opioid detection in a clinical setting. — Choucair I, Shang E, Tran MN, Cassella-McLane G, El-Khoury JM Clinica chimica acta; international journal of clinical chemistry (2025)
[20]
Guanidine-to-piperidine switch affords high affinity small molecule NPFF ligands with preference for NPFF1-R and NPFF2-R subtypes. — Galal KA, Obeng S, Pallares VLC, Senetra A, Seabra MABL, Awad A et al. European journal of medicinal chemistry (2024)
[21]
Nalbuphine-6-glucuronide is a potent analgesic with superior safety profiles by altering binding affinity and selectivity for mu-/kappa-opioid receptors. — Chen YL, Lai YH, Huang EY, Wang HJ, Hung HY Life sciences (2024)
[22]
Quantitative LC-MS/MS Analysis of Opiates and Opioids in Human Urine. — Gqamana PP, Zhang YV Methods in molecular biology (Clifton, N.J.) (2024)
[23]
Patient Controlled Subcutaneous Analgesia of Hydromorphone Versus Morphine to Treat Moderate and Severe Cancer Pain: A Randomized Double-Blind Controlled Trial. — Zeng X, Zhu J, Li J, Chen C, Sang L, Liu M et al. Journal of pain and symptom management (2024)
[24]
Ultramicronized — Toti A, Micheli L, Lucarini E, Ferrara V, Ciampi C, Margiotta F et al. Biomolecules (2023)
[25]
2,6-diazaspiro[3.4]octan-7-one derivatives as potent sigma-1 receptor antagonists that enhanced the antinociceptive effect of morphine and rescued morphine tolerance. — Fu K, Xu W, Yang R, Zhao H, Xu H, Wei Y et al. European journal of medicinal chemistry (2023)
[26]
Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. — Check DK, Baggett CD, Kim K, Merlin JS, Oeffinger KC, Winn AN et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
[27]
Primary Care and Mental Health Prescribers, Key Clinical Leaders, and Clinical Pharmacist Specialists' Perspectives on Opioids and Benzodiazepines. — Hawkins EJ, Lott AM, Danner AN, Malte CA, Hagedorn HJ, Berger D et al. Pain medicine (Malden, Mass.) (2021)
[28]
NB-33, a bioreversible opioid derivative of Nalbuphine, shows enhanced pharmacodynamics. — Voronkov M, Nikonov G, Naumov R, Abernethy J, Isakulyan L European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2021)
[29]
Chronic Opioid Therapy: A Scoping Literature Review on Evolving Clinical and Scientific Definitions. — Shen Y, Bhagwandass H, Branchcomb T, Galvez SA, Grande I, Lessing J et al. The journal of pain (2021)
[30]
Transitioning From Intrathecal Hydromorphone to Sublingual Buprenorphine-Naloxone Through Microdosing: A Case Report. — Crum IT, Meyer Karre VM, Balasanova AA A&A practice (2020)
[31]
Conversion of other opioids to methadone: a retrospective comparison of two methods. — Lukin B, Greenslade J, Kearney AM, Douglas C, Howell T, Barras M et al. BMJ supportive & palliative care (2020)
[32]
A Gas Chromatography-Triple Quadrupole Mass Spectrometry Assay for the Quantification of Opiates in Human Blood Samples. — Saad MAA, Abu-Rumman AM, Mohamed KM Journal of analytical toxicology (2019)
[33]
Effect of continuous intravenous oxycodone infusion in opioid-naïve cancer patients with dyspnea. — Yamamoto Y, Watanabe H, Sakurai A, Deguchi Y, Hirano S, Okumura Y et al. Japanese journal of clinical oncology (2018)
[34]
In vitro and in vivo release of dinalbuphine sebacate extended release formulation: Effect of the oil ratio on drug release. — Li CJ, Ku MY, Lu CY, Tien YE, Chern WH, Huang JD International journal of pharmaceutics (2017)
[35]
Degradation of Opioids and Opiates During Acid Hydrolysis Leads to Reduced Recovery Compared to Enzymatic Hydrolysis. — Sitasuwan P, Melendez C, Marinova M, Mastrianni KR, Darragh A, Ryan E et al. Journal of analytical toxicology (2016)
[36]
The rare Arg181Cys mutation in the μ opioid receptor can abolish opioid responses. — Skorpen F, von Hofacker S, Bjørngaard M, Skogholt AH, Dale O, Kaasa S et al. Acta anaesthesiologica Scandinavica (2016)
[37]
Opioid-based micro and nanoparticulate formulations: alternative approach on pain management. — São Pedro A, Fernandes R, Villarreal CF, Fialho R, Albuquerque EC Journal of microencapsulation (2016)
[38]
Associations of borderline personality with pain, problems with medications and suicidality in a community sample of chronic non-cancer pain patients prescribed opioids for pain. — Campbell G, Bruno R, Darke S, Degenhardt L General hospital psychiatry (2015)
[39]
Simultaneous Quantitation of 78 Drugs and Metabolites in Urine with a Dilute-And-Shoot LC-MS-MS Assay. — Cao Z, Kaleta E, Wang P Journal of analytical toxicology (2015)
[40]
Rescheduling of combination hydrocodone products: problems for long-term care practitioners. — Mattingly Ii TJ The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists (2015)
[41]
Opioid titration with sustained-release oxycodone and immediate-release morphine for moderate/severe cancer pain: a pilot assessment of the CoDem protocol. — Samolsky Dekel BG, Tomasi M, Vasarri A, Gori A, Adversi M, Castagnoli A et al. Journal of opioid management (2014)
[42]
Commonly used excipients modulate UDP-glucuronosyltransferase 2b7 activity to improve nalbuphine oral bioavailability in humans. — Wang HJ, Hsiong CH, Ho ST, Lin MJ, Shih TY, Huang PW et al. Pharmaceutical research (2014)
[43]
Design and implementation of software for automated quality control and data analysis for a complex LC/MS/MS assay for urine opiates and metabolites. — Dickerson JA, Schmeling M, Hoofnagle AN, Hoffman NG Clinica chimica acta; international journal of clinical chemistry (2013)
[44]
Modification of concomitant drug release from oil vehicles using drug-prodrug combinations to achieve sustained balanced analgesia after joint installation. — Thing M, Jensen SS, Larsen C, Østergaard J, Larsen SW International journal of pharmaceutics (2012)
[45]
Concomitant medication among persistent opioid users with chronic non-malignant pain. — Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OM Acta anaesthesiologica Scandinavica (2012)
[46]
Temperature-dependent enhancement of the antinociceptive effects of opioids in combination with gabapentin in mice. — Neelakantan H, Walker EA European journal of pharmacology (2012)
[47]
Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. — Roques BP, Fournié-Zaluski MC, Wurm M Nature reviews. Drug discovery (2012)
[48]
CART peptide in the nucleus accumbens shell acts downstream to dopamine and mediates the reward and reinforcement actions of morphine. — Upadhya MA, Nakhate KT, Kokare DM, Singh U, Singru PS, Subhedar NK Neuropharmacology (2012)
[49]
Twin and triplet drugs in opioid research. — Fujii H Topics in current chemistry (2011)
[50]
Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. — Krebs EE, Becker WC, Zerzan J, Bair MJ, McCoy K, Hui S Pain (2011)
[51]
Interferences with urine drug screens. — Herring C, Muzyk AJ, Johnston C Journal of pharmacy practice (2011)
[52]
Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administration. — Nagase H, Nemoto T, Matsubara A, Saito M, Yamamoto N, Osa Y et al. Bioorganic & medicinal chemistry letters (2010)
[53]
Long-term continuous subcutaneous infusion of ketoprofen combined with morphine: a safe and effective approach to cancer pain. — Moselli NM, Cruto M, Massucco P, Savojardo M, Debernardi F The Clinical journal of pain (2010)
[54]
Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives. — Cone EJ, Zichterman A, Heltsley R, Black DL, Cawthon B, Robert T et al. Forensic science international (2010)
[55]
Combination of low-dose nalbuphine and morphine in patient-controlled analgesia decreases incidence of opioid-related side effects. — Yeh YC, Lin TF, Chang HC, Chan WS, Wang YP, Lin CJ et al. Journal of the Formosan Medical Association = Taiwan yi zhi (2009)
[56]
Alvimopan. — Curran MP, Robins GW, Scott LJ, Perry CM Drugs (2008)
[57]
Combination of opioid agonist and agonist-antagonist: patient-controlled analgesia requirement and adverse events among different-ratio morphine and nalbuphine admixtures for postoperative pain. — Yeh YC, Lin TF, Lin FS, Wang YP, Lin CJ, Sun WZ British journal of anaesthesia (2008)
[58]
Morphine sulfate extended-release capsules for the treatment of chronic, moderate-to-severe pain. — Nicholson B Expert opinion on pharmacotherapy (2008)
[59]
Combination opioid analgesics. — Smith HS Pain physician (2008)
[60]
Comparing the efficacy and safety of continuous epidural analgesia in abdominal and urological surgery between two opioids with different kinetic properties: morphine and sufentanyl. — Delvecchio L, Bettinelli S, Klersy C, Allegri M, Cavalloro F, Braschi A Minerva anestesiologica (2008)
[61]
Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. — La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB Clinical pharmacology and therapeutics (2008)
[62]
Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. — Kokubun H, Fukawa M, Matoba M, Hoka S, Yamada Y, Yago K Biological & pharmaceutical bulletin (2007)
[63]
Long term methadone for chronic pain: a pilot study of pharmacokinetic aspects. — Fredheim OM, Borchgrevink PC, Klepstad P, Kaasa S, Dale O European journal of pain (London, England) (2007)
[64]
The depot of buprenorphine decanoate produced a dose-related long-lasting antinociceptive effect in guinea pigs. — Wu SZ, Liu KS, Chu KS, Cheng KI, Kuei CH, Wang JJ et al. Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists (2006)
[65]
Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. — Weinstein SM, Shi M, Buckley BJ, Kwarcinski MA Clinical therapeutics (2006)
[66]
Phospholipase Cbeta1 modulates pain sensitivity, opioid antinociception and opioid tolerance formation. — Liu NJ, vonGizycki H, Gintzler AR Brain research (2006)
[67]
The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. — Johnson EE, Christie MJ, Connor M Neuro-Signals (2005)
[68]
Oxycodone/Ibuprofen combination tablet: a review of its use in the management of acute pain. — Oldfield V, Perry CM Drugs (2005)
[69]
Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives. — Pothier J, Galand N Journal of chromatography. A (2005)
[70]
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. — Husbands SM, Neilan CL, Broadbear J, Grundt P, Breeden S, Aceto MD et al. European journal of pharmacology (2005)
[71]
Cyclic enkephalin analogs containing various para-substituted phenylalanine derivatives in place of Tyr1 are potent opioid agonists. — Weltrowska G, Lemieux C, Chung NN, Schiller PW The journal of peptide research : official journal of the American Peptide Society (2005)
[72]
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat. — Whiteside GT, Harrison JE, Pearson MS, Chen Z, Fundytus ME, Rotshteyn Y et al. The Journal of pharmacology and experimental therapeutics (2004)
[73]
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. — Valenzano KJ, Miller W, Chen Z, Shan S, Crumley G, Victory SF et al. The Journal of pharmacology and experimental therapeutics (2004)
[74]
Development and validation of a liquid chromatography-mass spectrometry assay for the determination of opiates and cocaine in meconium. — Pichini S, Pacifici R, Pellegrini M, Marchei E, Pérez-Alarcón E, Puig C et al. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2003)
[75]
An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. — Tse DM, Sham MM, Ng DK, Ma HM Palliative medicine (2003)
[76]
Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine. — Andersen G, Jensen NH, Christrup L, Hansen SH, Sjøgren P Palliative medicine (2002)
[77]
The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. — Cepeda MS, Africano JM, Manrique AM, Fragoso W, Carr DB Pain (2002)
[78]
The addition of morphine prolongs fentanyl-bupivacaine spinal analgesia for the relief of labor pain. — Yeh HM, Chen LK, Shyu MK, Lin CJ, Sun WZ, Wang MJ et al. Anesthesia and analgesia (2001)
[79]
Morphine or oxycodone in cancer pain? — Heiskanen TE, Ruismäki PM, Seppälä TA, Kalso EA Acta oncologica (Stockholm, Sweden) (2000)
[80]
Diazabicyclo[3.3.1]nonanone-type ligands for the opioid receptors. — Kuhl U, Englberger W, Haurand M, Holzgrabe U Archiv der Pharmazie (2000)
[81]
Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration. — Holmes DL, Thibaudeau K, L'Archevêque B, Milner PG, Ezrin AM, Bridon DP Bioconjugate chemistry (2000)
[82]
Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. — Miller MG, McCarthy N, O'Boyle CA, Kearney M Journal of pain and symptom management (1999)
[83]
Long-term stability of morphine and bupivacaine mixture for spinal use. — Essink-Tjebbes CM, Burger DM, Beelen M, Wuis EW, Hekster YA Pharmacy world & science : PWS (1999)
[84]
Helix-inducing alpha-aminoisobutyric acid in opioid mimetic deltorphin C analogues. — Bryant SD, Guerrini R, Salvadori S, Bianchi C, Tomatis R, Attila M et al. Journal of medicinal chemistry (1997)
[85]
Simultaneous identification and quantitation of codeine, morphine, hydrocodone, and hydromorphone in urine as trimethylsilyl and oxime derivatives by gas chromatography-mass spectrometry. — Broussard LA, Presley LC, Pittman T, Clouette R, Wimbish GH Clinical chemistry (1997)
[86]
Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. — Hagen NA, Babul N Cancer (1997)
[87]
Post-operative intravenous continuous analgesia: comparison of buprenorphine, fentanyl and nalbuphine. — Lejus C, Blanloeil Y, François T, Testa S, Michel P, Dixneuf B European journal of anaesthesiology (1996)
[88]
CCB, a novel specific kappa opioid agonist, which discriminates between opioid and sigma 1 recognition sites. — Ronsisvalle G, Prezzavento O, Pasquinucci L, Marrazzo A, Vittorio F, Gomez-Vidal JA et al. Life sciences (1995)
[89]
Analgesic potency of mu and kappa opioids after systemic administration in amphibians. — Stevens CW, Klopp AJ, Facello JA The Journal of pharmacology and experimental therapeutics (1994)
[90]
Locomotor and analgesic effects of morphine and acetorphan in rats chronically treated with morphine or thiorphan. — Khallouk-Bousselmame R, Costentin J European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology (1994)
[91]
Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids. — Banning A, Sjøgren P, Kaiser F Acta anaesthesiologica Scandinavica (1992)
[92]
Analgesic potency of TRIMU-5: a mixed mu 2 opioid receptor agonist/mu 1 opioid receptor antagonist. — Tive LA, Pick CG, Paul D, Roques BP, Gacel GA, Pasternak GW European journal of pharmacology (1992)
[93]
Spinal kappa receptor-mediated analgesia of E-2078, a systemically active dynorphin analog, in mice. — Nakazawa T, Furuya Y, Kaneko T, Yamatsu K The Journal of pharmacology and experimental therapeutics (1991)
[94]
Analgesia produced by E-2078, a systemically active dynorphin analog, in mice. — Nakazawa T, Furuya Y, Kaneko T, Yamatsu K, Yoshino H, Tachibana S The Journal of pharmacology and experimental therapeutics (1990)
[95]
Portable narcotic infusion devices in Canada. — Coons CE, Sone M The Canadian journal of hospital pharmacy (1989)
[96]
Continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer. — Bruera E, Brenneis C, Michaud M, Chadwick S, MacDonald RN Cancer treatment reports (1987)
[97]
Novel opiates and antagonists. 6. 7-Alkyl-6,7-didehydromorphinans. — Quick J, Herlihy P, Howes JF Journal of medicinal chemistry (1984)
[98]
Derivatives of beta-casomorphins with high analgesic potency. — Matthies H, Stark H, Hartrodt B, Ruethrich HL, Spieler HT, Barth A et al. Peptides (1984)
[99]
Narcotic maintenance for chronic pain. Medical and legal guidelines. — Tennant FS J, Uelmen GF Postgraduate medicine (1983)
[100]
A simple solid-phase radioimmunoassay for morphine and related opiates using a mixture of labelled morphine and antiserum pre-precipitated by polyethylene glycol. — Smith RN Journal of immunoassay (1981)